Nodular sclerosis Hodgkin lymphoma is the most common subtype. It often starts in lymph nodes in the chest or neck and is frequently diagnosed in younger adults. Under the microscope, bands of ...

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...

SAN ANTONIO -- Many patients with early breast cancer can safely skip sentinel lymph node biopsy (SLNB), results of a large Dutch study suggested. After 5 years, the regional recurrence-free survival ...

MSK hematologist-oncologist Dr. Lia Palomba led a clinical trial that resulted in FDA approval of lisocabtagene maraleucel (Breyanzi®), a CAR T cell therapy, for marginal zone lymphoma. Marginal zone ...

Please provide your email address to receive an email when new articles are posted on . Skipping sentinel lymph node biopsy can be considered for node-negative, HR-positive, HER2-negative early breast ...

To investigate this further, first author, Gabriella N. Tortorello, MD, and a research team from the University of Pennsylvania, performed a retrospective cohort study with data from the National ...

Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or ...

What Is Breyanzi, and Why Does It Matter? Breyanzi (lisocabtagene maraleucel) is a type of personalized cancer treatment called chimeric antigen receptor (CAR) T-cell therapy, which uses your modified ...

“The FDA approval of Breyanzi for relapsed or refractory marginal zone lymphoma further solidifies it as the leading CD19-directed CAR T cell therapy covering the broadest range of B-cell malignancies ...

Clinically meaningful responses were observed with sonrotoclax in heavily pretreated MCL patients. The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) ...